Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Leases: 2019-2025

Historic Current Leases for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to $2.3 million.

  • Keros Therapeutics' Current Leases rose 24.82% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 24.82%. This contributed to the annual value of $2.0 million for FY2024, which is 96.82% up from last year.
  • Keros Therapeutics' Current Leases amounted to $2.3 million in Q3 2025, which was up 3.95% from $2.2 million recorded in Q2 2025.
  • Keros Therapeutics' Current Leases' 5-year high stood at $2.3 million during Q3 2025, with a 5-year trough of $436,000 in Q1 2021.
  • For the 3-year period, Keros Therapeutics' Current Leases averaged around $1.6 million, with its median value being $1.9 million (2024).
  • Its Current Leases has fluctuated over the past 5 years, first plummeted by 47.22% in 2022, then surged by 203.93% in 2024.
  • Keros Therapeutics' Current Leases (Quarterly) stood at $862,000 in 2021, then plummeted by 47.22% to $455,000 in 2022, then surged by 120.88% to $1.0 million in 2023, then spiked by 96.82% to $2.0 million in 2024, then climbed by 24.82% to $2.3 million in 2025.
  • Its Current Leases stands at $2.3 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.1 million for Q1 2025.